NEW YORK, Nov. 15, 2021 /CNW/ — MindMed (Nasdaq: MNMD, NEO: MMED, DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, has announced its quarterly financial results for the quarter ended September 30, 2021. Third Quarter 2021 Financial Highlights (in USD) Cash Balance. Total assets as of September 30, 2021 were $178.6 million, including $145.9 million in cash…


Previous articleRed Light Holland Psilocybin Truffles, Sold in The Netherlands, Complete First Evaluation Under a Health Canada Approved cGMP Laboratory
Next articleMindMed Launches Study of Low-Dose LSD Effects on Sleep and Cognitive Measures